TY - JOUR
T1 - Identification of sokotrasterol sulfate as a novel proangiogenic steroid
AU - Murphy, Siun
AU - Larrivée, Bruno
AU - Pollet, Ingrid
AU - Craig, Kyle S.
AU - Williams, David E.
AU - Huang, Xin Hui
AU - Abbott, Megan
AU - Wong, Fred
AU - Curtis, Cameron
AU - Conrads, Thomas P.
AU - Veenstra, Timothy
AU - Puri, Mira
AU - Hsiang, York
AU - Roberge, Michel
AU - Andersen, Raymond J.
AU - Karsan, Aly
PY - 2006/8
Y1 - 2006/8
N2 - The potential to promote neovascularization in ischemic tissues using exogenous agents has become an exciting area of therapeutics. In an attempt to identify novel small molecules with angiogenesis promoting activity, we screened a library of natural products and identified a sulfated steroid, sokotrasterol sulfate, that induces angiogenesis in vitro and in vivo. We show that sokotrasterol sulfate promotes endothelial sprouting in vitro, new blood vessel formation on the chick chorioallantoic membrane, and accelerates angiogenesis and reperfusion in a mouse hindlimb ischemia model. We demonstrate that sulfation of the steroid is critical for promoting angiogenesis, as the desulfated steroid exhibited no endothelial sprouting activity. We thus developed a chemically synthesized sokotrasterol sulfate analog, 2β,3α,6α-cholestanetrisulfate, that demonstrated equivalent activity in the hindlimb ischemia model and resulted in the generation of stable vessels that persisted following cessation of therapy. The function of sokotrasterol sulfate was dependent on cyclooxygenase-2 activity and vascular endothelial growth factor induction, as inhibition of either cyclooxygenase-2 or vascular endothelial growth factor blocked angiogenesis. Surface expression of αvβ3 integrin was also necessary for function, as neutralization of αvβ3 integrin, but not β1 integrin, binding abrogated endothelial sprouting and antiapoptotic activity in response to sokotrasterol sulfate. Our findings indicate that sokotrasterol sulfate and its analogs can promote angiogenesis in vitro and in vivo and could potentially be used for promoting neovascularization to relieve the sequelae of vasoocclusive diseases.
AB - The potential to promote neovascularization in ischemic tissues using exogenous agents has become an exciting area of therapeutics. In an attempt to identify novel small molecules with angiogenesis promoting activity, we screened a library of natural products and identified a sulfated steroid, sokotrasterol sulfate, that induces angiogenesis in vitro and in vivo. We show that sokotrasterol sulfate promotes endothelial sprouting in vitro, new blood vessel formation on the chick chorioallantoic membrane, and accelerates angiogenesis and reperfusion in a mouse hindlimb ischemia model. We demonstrate that sulfation of the steroid is critical for promoting angiogenesis, as the desulfated steroid exhibited no endothelial sprouting activity. We thus developed a chemically synthesized sokotrasterol sulfate analog, 2β,3α,6α-cholestanetrisulfate, that demonstrated equivalent activity in the hindlimb ischemia model and resulted in the generation of stable vessels that persisted following cessation of therapy. The function of sokotrasterol sulfate was dependent on cyclooxygenase-2 activity and vascular endothelial growth factor induction, as inhibition of either cyclooxygenase-2 or vascular endothelial growth factor blocked angiogenesis. Surface expression of αvβ3 integrin was also necessary for function, as neutralization of αvβ3 integrin, but not β1 integrin, binding abrogated endothelial sprouting and antiapoptotic activity in response to sokotrasterol sulfate. Our findings indicate that sokotrasterol sulfate and its analogs can promote angiogenesis in vitro and in vivo and could potentially be used for promoting neovascularization to relieve the sequelae of vasoocclusive diseases.
KW - Angiogenesis
KW - Endothelium
KW - Ischemia
UR - http://www.scopus.com/inward/record.url?scp=33746837205&partnerID=8YFLogxK
U2 - 10.1161/01.RES.0000233316.17882.33
DO - 10.1161/01.RES.0000233316.17882.33
M3 - Article
C2 - 16794189
AN - SCOPUS:33746837205
SN - 0009-7330
VL - 99
SP - 257
EP - 265
JO - Circulation research
JF - Circulation research
IS - 3
ER -